# AbbVie Inc. (ABBV) · Edgar & Edgarette company card

> AbbVie (ABBV) grew revenue 8.6% in FY2025 to $61.2 billion, operating margin 24.6% against a -3.8% median for pharmaceutical preparations, equity -2.4% of assets, and dividend per share up 11 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1551152 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ABBV) · [JSON](https://www.pops4.com/boards/company/ABBV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $61.2B |
| Revenue growth, 1 year | 8.6% |
| Revenue growth per year | 2.1% |
| Operating margin | 24.6% (prior year 16.2%) |
| Net margin | 6.9% |
| Operating cash flow | $19.0B |
| Capital spending | $1.2B |
| Free cash flow | $17.8B |
| Cash | $5.2B |
| Long-term debt | $65.0B |
| Total assets | $134.0B |
| Total equity | −$3.3B |
| Equity ÷ assets | -2.4% |
| Return on equity | — |
| Dividend per share | $6.65 |
| Dividend years rising | 11 |

## Readings, computed from those figures

- Altman Z: -0.34 (distress zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.86 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · liabilities exceed assets (often from years of share buybacks, not always distress)
- Cash Compass: Steady earner · steady and paying a dividend, with average cash

## Edgarette's reading

Exposure: revenue $61.2B (FY2025), total debt $65.0B. Experience: revenue up 8.6% on the year, up 2.1% a year over 4 years; operating margin 24.6%, up from 16.2%. Soundness: equity -2.4% of assets (liabilities exceed assets), payout 275.4% of profit, dividend per share up 11 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $56.9B and $67.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $52.7B to $72.9B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 24.6% against a -3.8% median; growth 8.6% against 13.7%.

Range logged 2026-09-26, receipt 417b922c414f69c6, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-11-02 ([filing](https://www.sec.gov/Archives/edgar/data/1551152/000110465926121322/0001104659-26-121322-index.htm))

## Recent filings

- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm)
- 8-K · filed 2026-11-02 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1551152/000110465926121322/0001104659-26-121322-index.htm)
- 8-K · filed 2026-10-30 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/0001551152-26-000033-index.htm)
- 8-K · filed 2026-10-15 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1551152/000110465926116227/0001104659-26-116227-index.htm)
- 8-K · filed 2026-10-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000030/0001551152-26-000030-index.htm)
- 8-K · filed 2026-09-03 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/0001104659-26-104940-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001551152.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1551152

## Cite

POPS4, Edgar & Edgarette: AbbVie Inc. (ABBV) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/ABBV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.